TY  - CHAP
AU  - Ota Fuchs
ED  - Ota Fuchs
Y1  - 2021-07-28
PY  - 2021
T1  - Introductory Chapter: Oral Selinexor, a Selective Inhibitor of Nuclear Export in the Treatment of Patients with Multiple Myeloma Refractory to Proteasome Inhibitors, Immunomodulatory Agents and Monoclonal Antibodies
N2  - This book deals with the diagnosis and treatment of multiple myeloma. Multiple myeloma is a plasma cell disorder, the prognosis of which has dramatically improved in the last years thanks to new immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies, in relapsed/refractory disease and a diagnosis. Chapters cover such topics as prognostic and predictive factors in newly diagnosed multiple myeloma, treatment approaches, antibody therapies, and three-dimensional (3D) models mimicking multiple myeloma bone marrow–microenvironment interactions.
BT  - Multiple Myeloma
SP  - Ch. 1
UR  - https://doi.org/10.5772/intechopen.96945
DO  - 10.5772/intechopen.96945
SN  - 978-1-83968-621-4
PB  - IntechOpen
CY  - Rijeka
Y2  - 2024-04-26
ER  -